
Akrevia launches with $30M in Series A financing
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
In addition to the funding, which was led by Accel, Eight Roads Ventures and F-Prime Capital Partners, the company announced it has opened a new office in Cambridge, Massachusetts.
Oak HC/FT and F-Prime Capital Partners led the Series A round for the California startup, while Maverick Ventures and Greylock Partners participated.
The company plans to use blockchain and other technologies to develop the genomic data marketplace, under a partnership with Veritas Genetics.